Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

• Published in: Investigational new drugs 2008-10, Vol.26 (5), p.483-488
• Main Authors: Vansteenkiste, Johan, Van Cutsem, Eric, Dumez, Herlinde, Chen, Cong, Ricker, Justin L., Randolph, Sophia S., Schöffski, Patrick
• Format: Article
• Language: English
• Subjects: Administration, Oral; Adult; Aged; Anorexia; Breast cancer; Breast Neoplasms - drug therapy; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Chemotherapy; Colorectal cancer; Colorectal Neoplasms - drug therapy; Drug Administration Schedule; Drug dosages; Enrollments; Female; Gene expression; Humans; Hydroxamic Acids - administration & dosage; Hydroxamic Acids - adverse effects; Inhibitor drugs; Lung cancer; Lung Neoplasms - drug therapy; Male; Medicine; Medicine & Public Health; Middle Aged; Nausea; Oncology; Patients; Pharmacology; Pharmacology/Toxicology; Phase II Studies; Positron-Emission Tomography; Recurrence; Response rates; Thrombocytopenia; Toxicity; Tumors
• ISSN: 0167-6997; 1573-0646
• DOI: 10.1007/s10637-008-9131-6

Summary Vorinostat (Zolinza®) is a histone deacetylase inhibitor that has demonstrated activity in patients with advanced solid tumors in phase I trials. A multicenter, open-label phase II trial of oral vorinostat 200, 300 or 400 mg bid for 14 days followed by a 7-day rest until disease progression or intolerable toxicity was conducted. Patients with measurable, relapsed or refractory breast or non-small cell lung cancer who had received ≥1 prior therapy or colorectal cancer who had received ≥2 prior therapies were eligible. The response rate, safety and tolerability were evaluated. Sixteen patients (median age, 62 years; median 5.5 prior therapies) were enrolled. Six patients received 400 mg bid, six received 300 mg bid and four received 200 mg bid (14 days/3 weeks). Dose-limiting toxicities (DLTs) at the 400 or 300 mg bid levels were anorexia, asthenia, nausea, thrombocytopenia, vomiting, and weight loss. No DLTs were observed at the 200 mg bid level. Disease stabilization was observed in eight patients, but there were no confirmed responses. The median TTP was 33.5 days. Eleven patients discontinued due to clinical adverse experiences (AEs). The most common drug-related AEs were anorexia (81%), fatigue (62%), nausea (62%), diarrhea (56%), vomiting (56%), thrombocytopenia (50%) and weight loss (50%). Drug-related AEs ≥ grade 3 included thrombocytopenia (50%), anemia (12%), asthenia (12%) and nausea (12%). Vorinostat in a daily oral schedule for 14 days/3 weeks was tolerable at 200 mg bid only, and no responses were observed in this study. Most patients, however, had limited drug exposure which did not allow a reliable efficacy analysis.